Efficacy of Panobinostat for the Treatment of Multiple Myeloma

Panobinostat represents a potent oral nonselective pan-histone deacetylase inhibitor (HDAC) with activity in myeloma patients. It has been approved by the FDA and EMA in combination with bortezomib and dexamethasone for the treatment of multiple myeloma, in patients who have received at least two pr...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:J Oncol
Hlavní autoři: Eleutherakis-Papaiakovou, Evangelos, Kanellias, Nikolaos, Kastritis, Efstathios, Gavriatopoulou, Maria, Terpos, Evangelos, Dimopoulos, Meletios Athanasios
Médium: Artigo
Jazyk:Inglês
Vydáno: Hindawi 2020
Témata:
Review Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7201625/
https://ncbi.nlm.nih.gov/pubmed/32411240
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1155/2020/7131802
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky